12 Stocks on Jim Cramer’s Radar

Page 4 of 11

8. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holdings: 84

Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December has been a tumultuous month for them. On Tuesday, the stock dipped by 5.2% after the firm released its full-year 2026 guidance. The figures saw Pfizer Inc. (NYSE:PFE) forecast 2026 revenue to range between $59.5 billion to $62.5 billion and profit per share between $2.80 and $3. Both of these were below LSEG estimates. A key focus of the latest financial figures from Pfizer Inc. (NYSE:PFE) was the firm’s COVID-19 vaccine revenue as it shared that these sales would be $1.5 billion lower in 2026 over 2025’s figures.

Ahead of the release, Morgan Stanley had maintained an Equal-Weight rating and cut Pfizer Inc. (NYSE:PFE)’s share price target to $28 from $32. On December 17th, the bank adjusted the share price target to $27. Yet, on the same day, BMO maintained its $30 price target and an Outperform rating on Pfizer Inc. (NYSE:PFE)’s shares. As part of the release, it cited optimism about Pfizer Inc. (NYSE:PFE)’s cost-saving plans and the Metsera acquisition.

Cramer is tilted towards the optimistic side for Pfizer Inc. (NYSE:PFE). In his previous comments about the firm, the CNBC TV host has pointed out that CEO Dr. Albert Bourla could share important details at the JPMorgan Healthcare conference in January. In this appearance, he insisted that the CEO had a good hand:

“Yeah, Dr. Bourla’s struggling, he’s struggling because I think he’s got a good hand.”

Page 4 of 11